CO6382109A2 - Formulación de depósito de octreotida con niveles de exposición constantemente altos - Google Patents

Formulación de depósito de octreotida con niveles de exposición constantemente altos

Info

Publication number
CO6382109A2
CO6382109A2 CO11074834A CO11074834A CO6382109A2 CO 6382109 A2 CO6382109 A2 CO 6382109A2 CO 11074834 A CO11074834 A CO 11074834A CO 11074834 A CO11074834 A CO 11074834A CO 6382109 A2 CO6382109 A2 CO 6382109A2
Authority
CO
Colombia
Prior art keywords
octreotide
deposit
formulation
exposure levels
constantly high
Prior art date
Application number
CO11074834A
Other languages
English (en)
Spanish (es)
Inventor
Markus Ahlheim
Holger Petersen
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40520410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6382109(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of CO6382109A2 publication Critical patent/CO6382109A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/19Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/24Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO11074834A 2008-12-15 2011-06-15 Formulación de depósito de octreotida con niveles de exposición constantemente altos CO6382109A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08171712 2008-12-15

Publications (1)

Publication Number Publication Date
CO6382109A2 true CO6382109A2 (es) 2012-02-15

Family

ID=40520410

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11074834A CO6382109A2 (es) 2008-12-15 2011-06-15 Formulación de depósito de octreotida con niveles de exposición constantemente altos

Country Status (25)

Country Link
US (10) US20100151033A1 (enExample)
EP (1) EP2376070B1 (enExample)
JP (1) JP5721635B2 (enExample)
KR (1) KR101708517B1 (enExample)
CN (3) CN105233251A (enExample)
AR (1) AR074603A1 (enExample)
AU (1) AU2009336718B9 (enExample)
BR (1) BRPI0922607B1 (enExample)
CA (1) CA2746968C (enExample)
CL (1) CL2011001438A1 (enExample)
CO (1) CO6382109A2 (enExample)
EC (1) ECSP11011199A (enExample)
ES (1) ES2602614T3 (enExample)
IL (1) IL213034A (enExample)
MA (1) MA32964B1 (enExample)
MX (1) MX2011006335A (enExample)
MY (1) MY159789A (enExample)
NZ (1) NZ592998A (enExample)
PE (1) PE20110876A1 (enExample)
PL (1) PL2376070T3 (enExample)
PT (1) PT2376070T (enExample)
RU (1) RU2526822C2 (enExample)
SG (1) SG171255A1 (enExample)
TN (1) TN2011000261A1 (enExample)
WO (1) WO2010079047A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
BR112014028443B1 (pt) * 2012-05-14 2021-01-19 Teijin Limited composição estéril esterilizada com radiação
EP3125871B1 (en) * 2014-03-31 2020-10-21 Pharmathen S.A. Preparation of peptide loaded plga microspheres with controlled release characteristics
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
AU2016215350B2 (en) * 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
EP3681471B1 (en) 2017-09-15 2025-03-05 Oxular Limited Ophthalmic delivery device
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
GB9513224D0 (en) * 1995-06-29 1995-09-06 Sandoz Ltd Organic compounds
BR0315304A (pt) * 2002-11-06 2005-08-16 Alza Corp Formulações com depósito para liberação controlada
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20090092650A1 (en) * 2004-12-15 2009-04-09 Warren Stephen L Sustained Delivery Formulations of Octreotide Compounds
EP1968549B1 (en) * 2005-12-22 2014-05-14 Novartis AG Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Also Published As

Publication number Publication date
AU2009336718B2 (en) 2014-01-30
PE20110876A1 (es) 2011-12-21
AU2009336718B9 (en) 2014-04-03
WO2010079047A2 (en) 2010-07-15
US20140363513A1 (en) 2014-12-11
US20170143791A1 (en) 2017-05-25
US20160089336A1 (en) 2016-03-31
RU2011128538A (ru) 2013-01-20
CA2746968C (en) 2016-10-04
BRPI0922607A2 (pt) 2015-12-22
US20250205147A1 (en) 2025-06-26
US20180036230A1 (en) 2018-02-08
US20100151033A1 (en) 2010-06-17
AR074603A1 (es) 2011-01-26
IL213034A0 (en) 2011-07-31
PL2376070T3 (pl) 2017-04-28
TN2011000261A1 (en) 2012-12-17
ES2602614T3 (es) 2017-02-21
US20240082148A1 (en) 2024-03-14
ECSP11011199A (es) 2011-08-31
MY159789A (en) 2017-01-31
BRPI0922607B1 (pt) 2019-11-05
US20110262545A1 (en) 2011-10-27
SG171255A1 (en) 2011-07-28
RU2526822C2 (ru) 2014-08-27
PT2376070T (pt) 2016-11-16
AU2009336718A1 (en) 2011-06-30
CN105233251A (zh) 2016-01-13
CA2746968A1 (en) 2010-07-15
CL2011001438A1 (es) 2011-11-04
JP2012512147A (ja) 2012-05-31
MA32964B1 (fr) 2012-01-02
US20210161806A1 (en) 2021-06-03
EP2376070B1 (en) 2016-08-10
KR20110104042A (ko) 2011-09-21
JP5721635B2 (ja) 2015-05-20
CN105031607A (zh) 2015-11-11
HK1159505A1 (zh) 2012-08-03
US20190209462A1 (en) 2019-07-11
CN102245210A (zh) 2011-11-16
EP2376070A2 (en) 2011-10-19
NZ592998A (en) 2013-02-22
MX2011006335A (es) 2011-07-13
KR101708517B1 (ko) 2017-02-20
IL213034A (en) 2017-04-30
WO2010079047A3 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
CO6382109A2 (es) Formulación de depósito de octreotida con niveles de exposición constantemente altos
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
BR112012024428A2 (pt) composição farmacêutica de dissolução rápida
RU2014129620A (ru) Композиции, содержащие аморфный эмодепсид
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
MX2010008365A (es) Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
WO2012064302A3 (en) Improved montelukast formulations
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
WO2012078051A3 (en) IPN Vaccine
WO2012023024A3 (en) Controlled release formulations of dronedarone
EP2323984A4 (en) BIOACTIVE TWO-PHASE FORMULATIONS
TR201803451T4 (tr) Olmesartan formülasyonlari.
MX2015006011A (es) Pastilla medicinal a base de ibuprofeno sodico dihidratado.
CO6390098A2 (es) Formulaciones de desintegración rapida pre-compactadas de compuestos con baja biodisponibilidad oral.
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
EA201491167A1 (ru) Вагинальное кольцо, содержащее мелоксикам и агент для модулирования высвобождения активного ингредиента, для применения у женщин в качестве контрацептива для постоянного использования
EA201190243A1 (ru) Стабильная фармацевтическая композиция флударабина фосфата

Legal Events

Date Code Title Description
FC Application refused